For research use only. Not for therapeutic Use.
Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research[1].
Neboglamine hydrochloride (s.c. or p.o., 0.3-30 mg/kg) can regulate neuronal activity in brain regions and inhibit PCP-induced hypermobility in rats[1].
| Catalog Number | I042964 |
| CAS Number | 2759182-59-5 |
| Synonyms | (4S)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid;hydrochloride |
| Molecular Formula | C13H25ClN2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H24N2O3.ClH/c1-13(2)7-5-9(6-8-13)15-12(18)10(14)3-4-11(16)17;/h9-10H,3-8,14H2,1-2H3,(H,15,18)(H,16,17);1H/t10-;/m0./s1 |
| InChIKey | HBFGFOLPJKUNCS-PPHPATTJSA-N |
| SMILES | CC1(CCC(CC1)NC(=O)C(CCC(=O)O)N)C.Cl |
| Reference | [1]. Riccardo Chiusaroli, et al. Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat. Pharmacol Res. 2010 May;61(5):430-6. |
